Latest Biotech News

A TRACERx pilot analysis presented at AACR described how a tumor-informed whole-genome ctDNA sequencing approach using Ultima Genomics’ duplex sequencing method can detect intermediate-risk...

10x Genomics launched Atera, a new in situ spatial biology platform at AACR 2026, pitching whole-transcriptome profiling with single-cell resolution at higher throughput than its Xenium system....

Researchers reported early activity for KIR-CAR T cell therapy designed to target solid tumors by leveraging a natural killer cell-inspired mechanism. The experimental program aims to address a...

UCB agreed to acquire Neurona Therapeutics for $1.15 billion, adding NRTX-1001, a pluripotent stem-cell-derived therapy designed to produce GABA for people with drug-resistant mesial temporal lobe...

A machine learning model presented at AACR 2026 showed strong performance in predicting the tissue of origin for cancers of unknown primary (CUP) using DNA methylation data. Researchers from...

Nomic Bio partnered with Broad Clinical Labs to integrate Nomic’s Omni 1000 immunoassay platform into BCL’s omics and precision oncology offerings. The collaboration targets embedding proteomics...

Ledger Run upgraded its ClinRun platform to simplify how CROs and sponsors manage “invoiceables” when paying research sites. The system is designed to reduce manual invoice processing by...

ATCC and the Broad Institute reported engineered isogenic NSCLC models designed to replicate resistance mechanisms that emerge during EGFR-mutant treatment with osimertinib. The platform uses...

Eli Lilly announced it will acquire Kelonia Therapeutics for $3.25 billion upfront, as it accelerates its in vivo cell-therapy push. The deal adds a further $3.75 billion in potential clinical,...

UCB moved to expand its epilepsy pipeline with an $1.15 billion acquisition of Neurona Therapeutics. The transaction includes a $650 million upfront payment and up to $500 million in milestone...

GSK reported positive Phase I results for mocertatug rezetecan (Mo-Rez), its B7-H4 antibody-drug conjugate, in a BEHOLD-1 study spanning platinum-resistant ovarian cancer and recurrent endometrial...

Roche will expand its cancer monitoring footprint through an acquisition of MRD testing technology from SAGA Diagnostics, with Foundation Medicine set to integrate the platform. The deal is valued...

10x Genomics launched Atera, a new in situ spatial biology platform designed to deliver whole-transcriptome profiling at high throughput while raising the bar on plex capacity. The instrument is...

Revolution Medicines reported strong Phase III data for daraxonrasib (RASolute 302) in metastatic pancreatic ductal adenocarcinoma, pushing the once-undruggable KRAS space further into the...

Nektar Therapeutics updated investors on extended mid-stage results for rezpeg in severe alopecia areata, describing deeper hair-growth outcomes with longer treatment. The company said after one...

Leinco Technologies partnered with CellCarta to combine antibody portfolios for proteomics tools used in drug development and biomarker discovery. Leinco said the collaboration pairs its antibody...

ATCC and the Broad Institute reported engineered, isogenic cancer models that replicate resistance mechanisms to targeted therapies, starting with EGFR-mutant non-small cell lung cancer treated...

Ledger Run upgraded its ClinRun platform to streamline how clinical trials manage payments to research sites for “invoiceables” — site costs that fall outside pre-set budgets and are often hard to...

Roche struck a deal to buy Saga Diagnostics for up to $595 million, and Foundation Medicine is set to expand its molecular residual disease (MRD) offering through the acquisition of Saga’s...

Exact Sciences disclosed new evidence supporting its Oncodetect MRD test in early triple-negative breast cancer, presented by collaborators at AACR. The research reported an association between...